However, TARC/CCL17 levels have been found to vary between AD patients with similar disease severity scores [37], while some patients with severe AD may occasionally have normal or low levels of serum TARC/CCL17, findings reflecting the heterogeneity of AD pathogenesis [13,18]. This evidence concerns the gene CCL17 and Alzheimer disease.